MBX
MBX Biosciences, Inc.
$66.33
-0.03%
2026-08-21
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Key Fundamentals
P/E Ratio
4.51
Forward P/E
-17.39
EPS (TTM)
$-2.37
ROE
-33.2%
Profit Margin
0.0%
Debt/Equity
0.82
Price/Book
7.45
Market Cap
$3.30B
Avg Volume (10D)
450K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$72.64
60D Low
$28.01
Avg Volume
763K
Latest Close
$66.33
Get breakout alerts for MBX
Sign up for Breakout Scanner to receive daily notifications when MBX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
MBX Biosciences, Inc. (MBX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MBX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MBX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.